[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "CDC, Vaccines from 6 months", "description": "C.D.C. Recommends 2 Covid Vaccines for under 5s\n\nONS, \nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/antibodies\n\n95.9% of children aged 8 to 11 years had antibodies against SARS-CoV-2 \n\nCoronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age\n\nhttps://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children\n\nRisks of Myocarditis and Pericarditis\n\nThe FDA and CDC safety surveillance systems have previously identified increased risks of myocarditis and pericarditis following vaccination with the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine, particularly following the second dose. \n\nThe observed risk is highest in,\n\nmales 18 through 24 years of age for the Moderna\n\nmales 12 through 17 years of age for the Pfizer-BioNTech COVID-19 Vaccine. \n\nmost cases of myocarditis associated with the Moderna and Pfizer-BioNTech COVID-19 vaccines are characterized by rapid resolution of symptoms \n\nwith no impact on quality of life reported by most patients who were contacted for follow-up at 90 days or more after reporting myocarditis. \n\nhttps://www.nytimes.com/live/2022/06/18/world/covid-19-mandates-vaccine-cases\n\n19 million\n\nModerna for ages 6 months through 5 years\n\nPfizer-BioNTech ages 6 months through 4 years\n\nDr. Rochelle P. Walensky, the C.D.C.\u2019s director\n\nAll children 6 months and older, \n\nincluding those who have already been infected with the coronavirus, \n\nshould get a Covid vaccine\n\nTogether, with science leading the charge, we have taken\u202fanother important step forward in our nation\u2019s fight against Covid-19\n\nWe know millions of parents and caregivers are eager to get their young children vaccinated, and with today\u2019s decision, they can\n\nAlbert Bourla, Chairman and Chief Executive Officer, Pfizer\n\nWe know many parents in the U.S. have been eagerly awaiting an authorized vaccine for their children under 5 and we are proud to now offer them a vaccine option with a favorable safety profile\n\nPfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose\n\nhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-demonstrates-strong-immune\n\nVaccine efficacy was 80.3% in children 6 months to under 5 years of age. \n\nN = 1,678 had 3 doses, (omicron times)\n\nThis descriptive analysis was based on 10 symptomatic COVID-19 cases identified from seven days after the third dose and accrued as of April 29, 2022. \n\n(3 in the vaccine group, 7 in the placebo group)\n\nThe trial protocol specifies a formal analysis will be performed when at least 21 cases have accrued from seven days after the third dose. \n\nFinal vaccine efficacy data will be shared once available.\n\nPfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age\n\nhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-receives-fda-emergency-use\n\nMODERNA ANNOUNCES ITS COVID-19 VACCINE PHASE 2/3 STUDY IN CHILDREN 6 MONTHS TO UNDER 6 YEARS HAS SUCCESSFULLY MET ITS PRIMARY ENDPOINT\n\nhttps://investors.modernatx.com/news/news-details/2022/Moderna-Announces-its-COVID-19-Vaccine-Phase-23-Study-in-Children-6-Months-to-Under-6-Years-Has-Successfully-Met-Its-Primary-Endpoint/default.aspx\n\n6 months to 2 years, n = 2,500 enrolled\n\n2 to under 6, n = 4,200 enrolled\n\nRates of fever post vaccine, greater than 38\n\n6 months to 2 years, 17%\n\n2 years to under 6, 14.6%\n\n6 to 12 years, 23.9%\n\nVaccine efficacy\n\nSimilar antibody response to in 18- to 25-year-olds\n\n6 months to 2 years, 43.7%\n\n2 to under 6 years, 37.5%\n\nKaiser Family Foundation survey\n\nhttps://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-april-2022/\n\nPlan to get under 5s vaccinated, 18%\n\nDefinitely not, 27%\n\nTom Inglesby, Johns Hopkins Center for Health Security, Bloomberg School of Public Health\n\nThere\u2019s a lot of information and trust building that needs to happen\n\nHopefully, with time, people will have increasing confidence that it\u2019s both effective and safe\n\nNeither vaccine was tested against BA.4 and BA.5\n\n(exceptional immune escape)\n\nPeter Hotez, molecular virologist, National School of Tropical Medicine at Baylor College of Medicine, Houston\n\nThe pediatric vaccines, won\u2019t hold up that well in protecting against infection by the new subvariants\n\nBut they will still be very effective in preventing children from going to the hospital or the intensive care unit\n\nACIP Committee Members\n\nhttps://www.cdc.gov/vaccines/acip/members/index.html", "link": "https://www.youtube.com/watch?v=6Z7RyGWLqAM", "date_published": "2022-06-19 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Large covid percentage increases", "description": "US, Variant Proportions, omicron mutants proliferate \n\nhttps://covid.cdc.gov/covid-data-tracker/#variant-proportions\n\nBA.4 8.3%\n\nBA.5 13.3%\n\nEvolutionally driver\n\nVaccine immune escape\n\nMore severe?\n\nNo\n\nSame symptoms?\n\nYes\n\nHospital admissions\n\nUp 4.6% on the week\n\nSeven day average, 4,330\n\nUK covid\n\nhttps://coronavirus.data.gov.uk\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights\n\nWeek ending 11 June 2022\n\nPercentage testing positive increased in England, Wales, Scotland and Northern Ireland\n\nOmicron variants BA.4 and BA.5.\n\nPercentage that had COVID-19 in the week\n\n1,131,000 (1 in 50 people) in England\n\n64,800 (1 in 45 people) in Wales\n\n42,900 (1 in 45 people) in Northern Ireland\n\n176,900 (1 in 30 people) in Scotland\n\nDeaths involving COVID-19 fall\n\nWeek ending 3 June 2022\n\nUK, 211 deaths registered in the UK involving coronavirus\n\n258 fewer than the previous week\n\nTotal deaths registered in the UK, W/E 3rd June\n\n7,881\n\n(16% below the five-year average)\n\n186 deaths involving COVID-19 in England and Wales\n\n58.1% disease, underlying cause of death\n\n(64.9% in the previous week) \n\nAntibodies\n\n99.3% in England\n\n99.3% in Wales \n\n99.4% in Northern Ireland \n\n99.4% in Scotland\n\nProportion of those aged under 16 years\n\nAntibodies at or above 179ng/ml\n\n(23 to 26 May 2022)\n\nAged 8 to 11, 95.9% \n\nAged 12 to 15, 95.7%\n\nTesting negative means that an individual did not have enough antibodies to be detected in the test, not that they do not have any immune protection against the virus.", "link": "https://www.youtube.com/watch?v=GKz-ZIbBKGo", "date_published": "2022-06-18 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]